We work to expand access to high-quality biologics, including biosimilars, for patients around the world.
Investing for future generations
With expertise in bacterial and mammalian cell-derived biosimilars, developed using recombinant DNA technology, we manufacture these products in dedicated facilities to ensure precision, safety, and accessibility. Our biologics portfolio includes seven biosimilar products and one novel biologic, marketed across multiple countries, supporting patients in oncology and immunology.
At Dr. Reddy’s Biologics, collaboration is key to driving progress. We engage in in-licensing, out-licensing, and co-development partnerships to accelerate breakthroughs and expand treatment options. Our work with global leaders in biopharmaceutical space strengthens our position in the industry.
Our biologics capabilities extend beyond biosimilars. From biosimilars and novel biologics to cell and gene therapy and contract development and manufacturing (CDMO), we offer comprehensive biologics solutions. Supported by state-of-the-art research and manufacturing facilities, including EMA approved facility, we maintain high standards to ensure reliability in every aspect of development and production.
With over 1 million patients treated globally, we continue to focus on responsible development and trusted partnerships. Our proposed biosimilars, currently under review by the US FDA, represents our ongoing efforts to improve biologics accessibility. Additionally, our biologics portfolio includes partnerships to develop and bring innovative therapeutic solutions designed to support critical patient needs.
Dr. Reddy’s Biologics remains dedicated to expanding access to advanced therapies through scientific progress, responsible development, and reliable manufacturing.
Learn more about our Biologics business